TMS for Sympathetic Hyperactivity and Inflammation in Acute Myocardial Infarction

The goal of this clinical trial is to learn whether repetitive transcranial magnetic stimulation (rTMS) can improve sympathetic hyperactivity and inflammatory responses in patients with acute myocardial infarction (AMI), as well as evaluate its safety and tolerability. The main questions it aims to answer are: Can 1-Hz low-frequency rTMS targeting the right dorsolateral prefrontal cortex improve heart rate variability (SDNN) among patients with acute myocardial infarction? Is rTMS safe and well-tolerated for patients with acute myocardial infarction? Researchers will compare real rTMS versus sham rTMS to see if real rTMS can reduce sympathetic over-activation and inflammation in AMI patients. Participants will: * Receive either real repetitive transcranial magnetic stimulation or sham stimulation for 7 consecutive days on top of standard-of-care medication for AMI * Complete clinical assessments including electrocardiogram, Holter monitoring, echocardiography, blood laboratory tests for inflammatory markers at baseline, day 7, day 30, and 3-month follow-up * Undergo resting-state functional magnetic resonance imaging (rs-fMRI) scans at baseline and day 7 * Fill out psychological and quality-of-life questionnaires (PHQ-9, SF-36) at scheduled study visits * Attend follow-up clinic visits to record adverse events and major adverse cardiovascular events